Skip to main content

ROIVANT SOCIAL VENTURES INC

EIN: 83-3947490New York, NYZIP: 10036

Mission

SEE SCHEDULE OOUR MISSION IS TO IMPROVE EQUITY IN HEALTH CARE ACCESS AND OUTCOMES ACROSS GEOGRAPHIES, SOCIOECONOMICS, AND DEMOGRAPHICS ON A NOT-FOR-PROFIT, CHARITABLE BASIS. WE USE INNOVATIONS IN SCIENCE AND TECHNOLOGY TO CHALLENGE AND ADVANCE THE NORMS OF BIOPHARMA AND HEALTH CARE DELIVERY. OUR WORK IS ACROSS TWO STRATEGIES: (I) INVESTMENTS AND INCUBATION LEADERSHIP TO EARLY-STAGE INNOVATIVE HEALTH ACCESS, MANUFACTURING, AND DRUG DEVELOPMENT ORGANIZATIONS WITH NO OR LOW-COST "PATIENT" CAPITAL AND RESOURCES; (II) CHARITABLE PARTNERSHIPS AND EDUCATIONAL INITIATIVES ACROSS INDUSTRY, PATIENT ADVOCACY, AND INVESTORS ACCELERATING DEVELOPMENT OF NEW MEDICINES.

Financials

YearRevenueExpensesAssets
2023$124k$0$627k
2022$183k$0$756k

Compensation

2023

ERIC VENKER
$0
$0
$0
$21,874
DANIEL PATTERSON
$0
$0
$0
$8,651

2022

MATTHEW GLINE
$0
$0
$0
$47,233,582
ERIC VENEKER
$0
$0
$0
$47,223,912
DANIEL PATTERSON
$0
$0
$0
$207,413

Explore related organizations

Similar Organizations

$112k revenue
Same sector (T30)Very similar revenue ($112k vs $124k)Same state (New York)
$105k revenue
Same sector (T30)Similar revenue ($105k vs $124k)Same state (New York)
$101k revenue
Same sector (T30)Similar revenue ($101k vs $124k)Same state (New York)
$149k revenue
Same sector (T30)Similar revenue ($149k vs $124k)Same state (New York)
$138k revenue
Same sector (T30)Similar revenue ($138k vs $124k)Same state (New York)
$101k revenue
Same sector (T30)Similar revenue ($101k vs $124k)Same state (New York)
$84k revenue
Same sector (T30)Comparable revenue ($84k vs $124k)Same state (New York)Similar size (9 vs 10 executives)
Similar sector (T)Very similar revenue ($132k vs $124k)Same state (New York)Similar size (8 vs 10 executives)
$163k revenue
Same sector (T30)Comparable revenue ($163k vs $124k)Same state (New York)
$113k revenue
Similar sector (T)Very similar revenue ($113k vs $124k)Same state (New York)

Learn more

Data from IRS Form 990 filings (2022-2023).